MARKET

ISEE

ISEE

IVERIC bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.420
-0.390
-8.11%
Closed 16:00 07/10 EDT
OPEN
4.800
PREV CLOSE
4.810
HIGH
4.840
LOW
4.160
VOLUME
1.96M
TURNOVER
--
52 WEEK HIGH
8.97
52 WEEK LOW
0.9059
MARKET CAP
391.12M
P/E (TTM)
-3.2235
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ISEE stock price target is 14.00 with a high estimate of 15.00 and a low estimate of 13.00.

EPS

ISEE News

More
Moving Average Crossover Alert: IVERIC bio
Zacks · 07/03 11:31
Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/02 07:14
Iveric bio launches second pivotal study of Zimura in eye disorder
Seeking Alpha - Article · 06/30 12:52
IVERIC bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Business Wire · 06/30 12:30
FDA rejects Allergan application for wet AMD drug
Seeking Alpha - Article · 06/26 10:33
Iveric Bio: Pick Up Post-Fundraising Low And Hold For Good News
Seeking Alpha - Article · 06/25 16:29
IVERIC bio, Inc. Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds
IVERIC bio, Inc. announced the closing of public offering and concurrent private placement with $160 million in gross proceeds.
Business Wire · 06/22 21:16
AAL, LTHM among premarket losers
Seeking Alpha - Article · 06/22 12:15

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About ISEE

IVERIC bio, Inc., formerly Ophthotech Corporation, is a biopharmaceutical company. The Company is focused on the discovering and developing of novel gene therapy solutions to treat orphan inherited retinal diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. The Company’s BEST1 gene encodes a multifunctional protein known as bestrophin1, that regulates ion transport and intracellular calcium signaling in retina cells and helps maintain homeostasis in the sub retinal space between photoreceptors and the retinal pigment epithelial (RPE) cells. Its IC-200 is a mutation independent gene therapy, delivered by an AAV2 vector.
More

Webull offers kinds of IVERIC bio Inc stock information, including NASDAQ:ISEE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ISEE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ISEE stock methods without spending real money on the virtual paper trading platform.